Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;7(6):3374-3382.
doi: 10.1002/ehf2.13066. Epub 2020 Oct 22.

Lateral left ventricular lead position is superior to posterior position in long-term outcome of patients who underwent cardiac resynchronization therapy

Affiliations

Lateral left ventricular lead position is superior to posterior position in long-term outcome of patients who underwent cardiac resynchronization therapy

Anett Behon et al. ESC Heart Fail. 2020 Dec.

Abstract

Aims: Preferring side branch of coronary sinus during cardiac resynchronization therapy (CRT) implantation has been empirical due to the limited data on the association of left ventricular (LV) lead position and long-term clinical outcome. We evaluated the long-term all-cause mortality by LV lead non-apical positions and further characterized them by interlead electrical delay (IED).

Methods and results: In our retrospective database, 2087 patients who underwent CRT implantation were registered between 2000 and 2018. Those with non-apical LV lead locations were classified into anterior (n = 108), posterior (n = 643), and lateral (n = 1336) groups. All-cause mortality was assessed by Kaplan-Meier and Cox analyses. Echocardiographic response was measured 6 months after CRT implantation. During the median follow-up time of 3.7 years, 1150 (55.1%) patients died-710 (53.1%) with lateral, 78 (72.2%) with anterior, and 362 (56.3%) with posterior positions. When we investigated the risk of all-cause mortality, there was a significantly lower rate of death in patients with lateral LV lead location when compared with those with an anterior (P < 0.01) or posterior (P < 0.01) position. Multivariate analysis after adjustment for relevant clinical covariates such as age, sex, ischaemic aetiology, left bundle branch block morphology, atrial fibrillation, and device type revealed consistent results that lateral position is associated with a significant risk reduction of all-cause mortality when compared with anterior [hazard ratio 0.69; 95% confidence interval (CI) 0.55-0.87; P < 0.01] or posterior (hazard ratio 0.84; 95% CI 0.74-0.96; P < 0.01) position. When echocardiographic response was evaluated within the lateral group, patients with an IED longer than 110 ms (area under the receiver operating characteristic curve, 0.63; 95% CI 0.53-0.73; P = 0.012) showed 2.1 times higher odds of improvement in echocardiographic response 6 months after the implantation.

Conclusions: In this study, we proved in a real-world patient population that after CRT implantation, lateral LV lead location was associated with long-term mortality benefit and is superior to both anterior and posterior positions. Moreover, patients with this position showed the greatest echocardiographic response over 110 ms IED.

Keywords: CRT long-term outcome; Interlead electrical delay; Lateral left ventricular lead; Left ventricular lead position; RV-LV delay.

PubMed Disclaimer

Conflict of interest statement

B.M. receives lecture fees from Biotronik, Medtronic, and Abbott. Other authors declare that they have no conflicts of interest regarding this manuscript.

Figures

Figure 1
Figure 1
Interlead electrical delay (IED) length by left ventricular lead locations. IED was significantly longer in the lateral group than in others (lateral vs. anterior P < 0.01) (lateral vs. posterior P < 0.01). The boxes represent the 95% confidence interval, with the whiskers representing the minimum and maximum range. The central horizontal lines within the boxes represent the median levels for each group.
Figure 2
Figure 2
Kaplan–Meier estimates of the probability of survival by left ventricular (LV) lead locations. Patients with lateral LV lead position had significantly better outcome compared with other locations.
Figure 3
Figure 3
Receiver operating characteristic (ROC) curve of interlead electrical delay (IED) length to echocardiographic response in patients with lateral left ventricular lead location. There was a significant association between IED and echocardiographic response (area under the ROC curve, 0.63; 95% confidence interval 0.53–0.73; P = 0.012) in the lateral group, with an optimal cut‐off value of 110 ms.

References

    1. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW. Cardiac‐resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140–2150. - PubMed
    1. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, Cardiac Resynchronization‐Heart Failure (CARE‐HF) Study Investigators . The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539–1549. - PubMed
    1. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W, MADIT‐CRT Trial Investigators . Cardiac‐resynchronization therapy for the prevention of heart‐failure events. N Engl J Med 2009; 361: 1329–1338. - PubMed
    1. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL, Resynchronization‐Defibrillation for Ambulatory Heart Failure Trial Investigators . Cardiac‐resynchronization therapy for mild‐to‐moderate heart failure. N Engl J Med 2010; 363: 2385–2395. - PubMed
    1. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Longer‐term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization‐Heart Failure (CARE‐HF) trial extension phase]. Eur Heart J 2006; 27: 1928–1932. - PubMed